Company ProfilePremium

Benjamin Hornigold Limited

Company Profile Analysis

Ticker: BHD.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Benjamin Hornigold Limited - Company showcase

Year Founded & Workforce

2016

Benjamin Hornigold Limited logo

Benjamin Hornigold Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Benjamin Hornigold Limited Overview

Benjamin Hornigold Ltd is a Sydney-based, internally governed micro-cap listed investment company. It runs an opportunistic, absolute-return mandate across ASX-listed securities and selected listed or unlisted funds. It was floated in 2017 under external management by John Bridgeman Ltd (JBL). That relationship ended in governance failure: related-party payments, loans to JBL-group entities, a 2018 ASX suspension, an attempted takeover by JBL blocked by the Takeovers Panel, and later ASIC criminal charges against the former CEO and CFO. Since June 2019 an entirely new three-person board, chaired by small-cap fund manager Michael Glennon, has managed the portfolio itself. It uses four stated strategies: discount capture on LICs trading below NTA, merger arbitrage, deep value and event-driven investing. The company's investment case now rests on three things: a portfolio of roughly A$3m, A$3.8m of cash at June 2026, and the conversion of legacy legal claims into cash. In mid-2026 the company received A$2.6m in settlements, which lifted NTA to about 34 cents.


Company's own description (paraphrased from the FY2023 Annual Report and FY2026 Appendix 4E). BHD describes itself as a listed investment company that gives investors exposure to an actively managed portfolio. The portfolio holds a small number of high-conviction investments in undervalued assets, aiming for above-average returns while limiting volatility over the medium to long term. Its stated investment objective is moderate to high portfolio returns over the medium to long term. The company characterises its style as "opportunistic", targeting an absolute return. The monthly NTA reports list the four primary strategies:

Discount capture: buying LICs that trade at large discounts to NTA.

Arbitrage: typically later-stage takeover situations, sometimes with short positions used to hedge market exposure.

Deep value: overlooked or out-of-favour securities where a re-rating is expected.

Event-driven: positions taken ahead of an anticipated catalyst.

Business model. BHD is a closed-end investment company. It raises permanent equity capital once, invests it, and generates returns through:

  • realised and unrealised gains on investments;

  • dividend and distribution income;

  • interest on cash;

  • since 2026, litigation recoveries.

It charges no fees to third parties and has no customers in the commercial sense. Its "product" is its own shares, which give exposure to the portfolio. Since the June 2019 board change there has been no external investment manager and no management or performance fee. Running costs are directors' fees (A$308,000 in FY2026), professional and legal fees (A$685,687 in FY2026) and minor administration costs.

Revenue model mix (FY2026; source: FY2026 Appendix 4E, Note 5).

Percentages do not sum to 100 because the realised and unrealised lines offset each other. In product, service, subscription or licensing terms, 100% of income is investment income. There is no product, service, subscription or licensing revenue.

Value-chain position. BHD is an end investor (asset owner) at the bottom of the capital-markets value chain. Its counterparties are:

  • stockbrokers, for execution;

  • the share registry (MUFG Corporate Markets);

  • the auditor (Pitcher Partners);

  • legal advisers, who are a major cost centre;

  • the investee companies and funds themselves.

"Customer" types. The shareholder base is concentrated and retail- and SMSF-heavy. At 18 August 2023 there were 345 holders, the top 20 held 75.45%, and 76 holders had less than a marketable parcel (FY2023 Annual Report). Strategic and activist holders include:

  • Glennon Small Companies Ltd / Glennon Capital, about 21.4%;

  • Keybridge Capital Ltd, about 15.4%;

  • director Sulieman Ravell's interests, about 11.3%.

End-markets. Australian listed equities, listed property trusts and REITs, closed-end private-equity feeder funds and other LICs. The company reports operating in a single geographic segment (Australia), although some investee vehicles hold offshore assets. The Cordish Dixon private-equity funds, for example, invest in US private markets.

Independent characterisation. In substance BHD is a post-crisis "recovery LIC". Its economic value has three parts:

  1. a modest, liquid, deep-value equity portfolio of about A$2.9m at June 2026;

  2. a large cash balance (A$3.78m at June 2026, about 56% of total assets), held partly to fund litigation;

  3. a set of legal claims arising from the 2017–2018 related-party transactions with the JBL group.

Those claims had a contractual face value of about A$8.6m and were fully impaired. In June–August 2026 the board crystallised A$2.6m of recoveries. It also obtained an A$8.97m default judgment against JB Markets Pty Ltd, to which it ascribes no value. The cost base (about A$1.0m in FY2026 including legal fees) is very high relative to net assets of A$5.7m. The next phase is therefore likely to turn on capital management, whether that is a return of capital, a buy-back, a merger with a related LIC or a wind-up, rather than on portfolio performance alone. This is an analyst inference. The board's only stated intention so far is to explore capital management options (Kalkine summary of the 20 July 2026 Litigation Update).

Strategy

Stated strategic themes (paraphrased from the FY2023 Annual Report and 2026 NTA reports):

  1. Capital preservation first. The board deploys capital gradually and holds high cash levels, historically 25–30% and about 56% of total assets at June 2026, partly to fund the pursuit of loan recoveries.

  2. Wide, flexible mandate. It uses four opportunistic strategies (discount capture, arbitrage, deep value, event-driven) and targets absolute returns.

  3. Maximising return of capital from investments. The FY2023 report says the company will continue as an LIC focused on achieving the maximum return of capital from its investments.

  4. Recovery of legacy assets. The board pursues the claims it judges most likely to succeed and produce cash. It has warned shareholders that litigation costs would weigh on NTA in the interim.

Medium-term financial targets and guidance. None published. BHD gives no earnings guidance, NTA targets or cost-reduction targets. Sustainability and ESG commitments: none disclosed. The company states it is not subject to significant environmental regulation.

Products & Services

BHD has no products, brands, platforms or services for sale. The closest equivalents are:

  1. the listed security itself (BHD ordinary shares), which is the "product" sold to investors;

  2. its four investment strategies;

  3. its disclosed portfolio holdings, which are its working capital.

These are catalogued below so the full exposure is visible.

5.1 The listed security

5.2 Investment strategies

5.3 Disclosed significant holdings (31 July 2026; source: NTA announcement, 14 August 2026)

The company notes that other large holdings may remain undisclosed.

5.4 Historical full holdings list (30 June 2023; source: FY2023 Annual Report, supplementary information)

5.5 Legacy claims portfolio (contingent assets; source: FY2026 Appendix 4E, Note 18)

Product Portfolio

AttributeDetail (source: FY2026 Appendix 4E)

Instrument

Fully paid ordinary shares, ASX: BHD

Shares on issue

24,155,241

Options / convertibles on issue

Nil

Dividend status

No dividends paid in FY2022–FY2026. Profit reserve of A$1,496,543 "preserved for future dividend payments"; franking credits of A$510,016 available

Fees

No external management fee or performance fee since 2019

Pricing

Exchange-traded. Historically at a large discount to NTA (A$0.18 price vs about A$0.24 NTA at 30 June 2026, about a 25% discount)

StrategyDescription (paraphrased from the 14 August 2026 NTA report)Example exposure

Discount capture

Buy LICs and closed-end funds trading at wide discounts to NTA

Cordish Dixon Private Equity Funds I, II, III

Arbitrage

Late-stage takeover targets; may short to hedge

Not individually disclosed

Deep value

Overlooked securities expected to re-rate

Navigator Global Investments, HealthCo Healthcare & Wellness REIT, Humm Group, Kyron Capital Group

Event-driven

Positions ahead of an anticipated catalyst

Not individually disclosed

HoldingAllocation (% of portfolio)StrategyRationale (paraphrased)

Cordish Dixon Private Equity Funds I, II, III

18.06

Deep value / discount capture

Maturing US private-equity funds of funds, bought at large discounts to NTA and now distributing capital

Navigator Global Investments (ASX: NGI)

7.80

Deep value

Holds strategic stakes in diversified alternative asset managers

HealthCo Healthcare & Wellness REIT (ASX: HCW)

6.10

Deep value

Hospital and health property REIT trading at a deep discount to NTA because of uncertainty over major tenant Healthscope; board believes most downside is priced in

Kyron Capital Group (formerly Elanor Investors Group)

3.11

Deep value

Property funds manager re-quoted in June 2026 after nearly two years of suspension following 2024 covenant breaches; board sees it as undervalued relative to about A$1.85bn of funds under management

Humm Group Ltd (ASX: HUM)

2.93

Deep value

Profitable non-bank lender trading below book value

HoldingMarket value at 30 June 2023 (AUD)

Kiland Ltd

574,100

CD Private Equity Fund II

560,292

Unibail-Rodamco-Westfield

513,975

CD Private Equity Fund III

483,660

Elanor Investors Group

337,361

Link Administration Holdings

264,555

Humm Group

228,340

Sequoia Financial Group

209,214

Navigator Global Ltd

177,322

CD Private Equity Fund I

135,637

Bailador Technology Investments

133,975

Carindale Property Trust

133,163

Aurizon Holdings

120,513

Iperionx Ltd

111,500

Platinum Asset Management

95,700

1851 Emerging Companies Fund (other investment)

87,678

Kogan.com

83,473

Qoria Ltd

79,875

NAOS Ex-50 convertible bond

56,700

Elanor Retail Property Fund

29,040

Total investments

4,416,074

ClaimContractual amount at 30 June 2026 (AUD)30 June 2025 (AUD)Carrying value

JBFG convertible loan plus interest

4,936,3114,483,950

Nil

JBL loan plus interest

2,058,6951,836,057

Nil

JBFG loan plus interest

1,630,5321,490,695

Nil

Overpaid performance fee

53,77353,773

Nil

Default judgment against JB Markets (6 August 2026)

8,971,570—

Nil (no value attributed)

Financial Narrative

Sources.

  • FY2022 and FY2023: FY2023 Annual Report (audited).

  • FY2025 and FY2026: FY2026 Appendix 4E (FY2026 unaudited; FY2025 comparatives audited).

  • FY2024: net result, closing equity, closing cash and closing investments are taken from comparatives and the reconciliations in the FY2026 report. The FY2024 income statement detail and total assets were not in the sources reviewed and are left blank.

All figures are in A$ thousands unless stated.

6.1 Income statement

Notes:

  • FY2024 EPS is derived as the A$566,926 loss divided by 24,155,241 shares.

  • The FY2026 commentary text gives the FY2025 loss as A$709,147 while the tables show A$709,247. The A$709,247 figure is used here; the A$100 difference appears to be a typographical error.

  • Gross profit, operating income and EBITDA are not meaningful for an LIC with no cost of sales, depreciation or debt. For BHD, operating income is effectively the pre-tax result, and EBITDA equals the pre-tax result less interest income.

6.2 Margins and growth

Notes:

  • The FY2022 net margin is not meaningful because total income was negative.

  • Revenue CAGR is not meaningful: total income was negative in FY2022 and is missing for FY2024. From FY2023 to FY2026, total income fell from A$905.8k to A$619.1k, a compound change of about -11.9% a year. This mainly reflects the end of interest accruals on impaired loans.

6.3 Balance sheet (30 June)

Notes:

  • Working capital equals net assets because the balance sheet is presented on a liquidity basis with no non-current liabilities.

  • Book value per share is equity divided by 24,155,241 shares.

6.4 Cash flow

Notes:

  • As is usual for an LIC, investment purchases and sales are classified as operating cash flows.

  • FY2024 operating cash flow is derived from the change in cash (A$3,540,210 less A$3,287,667), because investing and financing flows were nil in every year reviewed.

  • Free cash flow equals operating cash flow because there is no capex.

6.5 Ratios

Notes:

  • The company's return figures come from the FY2023 Annual Report and FY2026 Appendix 4E. The small FY2022 difference against the computed ROE (-17% vs -15.6%) probably reflects a different denominator definition.

  • ROIC equals ROE because there is no debt. Net debt/EBITDA and interest coverage are not applicable (no debt and no interest expense). The cash conversion cycle is not applicable (no inventory or trade receivables).

  • The FY2026 jump in payables to A$1,056,538 (from A$423,878) is the main reason the liquidity ratio fell. It most likely reflects accrued legal fees ahead of the July 2026 final hearing. This is an inference; the composition is not disclosed.

6.6 Commentary on trends, inflections and drivers

Shrinking capital base: Net assets fell in four of the five years, from A$8.55m at 1 July 2021 to A$5.71m at 30 June 2026, a 33% decline. With no capital raisings, dividends or buy-backs, this is almost entirely the cumulative effect of losses. Cumulative losses over FY2022–FY2026 were A$2.85m, of which FY2022 (A$1.24m) was the worst year.

Cost drag: The fixed cost base has become the dominant driver of returns:

  • directors' fees have been roughly flat at about A$303k–308k;

  • professional fees, mostly legal, rose from A$187,775 in FY2023 to A$524,585 in FY2025 and A$685,687 in FY2026.

Total expenses equalled about 17.6% of average equity in FY2026. A portfolio of about A$3m invested in risk assets cannot plausibly earn that back. This is why the litigation outcome dominates the investment case.

Portfolio returns: - The investment portfolio itself has been reasonably resilient. The board reported a gross portfolio return of 9.83% in FY2023, against 14.7% for the S&P/ASX 200 Accumulation Index and 8.45% for the Small Ordinaries Accumulation Index. In FY2022 it reported -5.97%, against -6.47% for the ASX 200 and -19.5% for the Small Ordinaries (FY2022 Financial Report). This was achieved with 25–30% held in cash.

  • FY2026 was positive at the portfolio level, with a net gain of A$534,741 from the investment portfolio. The overall loss came from costs.

  • The FY2026 Remuneration Report states that the portfolio underperformed the ASX 200 Accumulation Index.

Accounting quirk in FY2022–FY2023 income: Reported interest income of A$560k–665k included contractual interest accrued on defaulted JBL-group loans, which was simultaneously impaired. The FY2023 detail shows A$338,957 of convertible-loan interest and A$264,717 of other loan interest, all fully provided for. From FY2025 the company stopped recognising this interest in profit and loss. That explains the step-down in reported interest income to about A$84k, which is now genuine cash interest.

Post-balance-date inflection: The A$2.6m of settlement cash received in July–August 2026 is not in the FY2026 accounts. It is roughly equal to 46% of 30 June 2026 equity. On a simple pro forma basis it lifts NTA to about A$8.3m, or about 34.4 cents per share, before any related legal costs. This is consistent with the reported 31 July 2026 NTA of 34.10 cents.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Results by Segment and Revenue by Segment (%)

MetricFY2022FY2023FY2024FY2025FY2026

Segment total income (AUD K)

-171.3905.8—183.0619.1

Segment pre-tax result (AUD K)

-1,239.087.4-566.9-709.2-420.9

Segment share of total income (%)

100100100100100

Function Details

FunctionResponsible party

Portfolio management

Board, led by Chair Michael Glennon (career small-cap portfolio manager)

Company secretarial

Michael Glennon

Audit & Risk Committee

Full board; chaired by Gary Miller

Remuneration Committee

Chaired by Gary Miller; held no meetings in FY2023

Litigation oversight

Board, with external solicitors

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Net gain/(loss) from investment portfolio (AUD K)

-870.5240.3—98.5534.7

Dividend income (AUD K)

146.4114.9—38.024.7

Other income from investments (AUD K)

270.3375.1—410.8616.8

Net realised gain/(loss) on investments (AUD K)

536.6-485.3—-141.0518.1

Interest income (AUD K)

560.0665.3—84.584.4

Other revenue / cost recoveries (AUD K)

139.30.3—00

Total income (AUD K)

-171.3905.8—183.0619.1

Total expenses (AUD K)

1,067.8818.4—892.21,040.1

Directors' fees (AUD K)

302.5303.9—306.6308.0

Professional fees (AUD K)

266.8187.8—524.6685.7

Impairment of receivables (AUD K)

446.5264.7—00

Pre-tax profit (AUD K)

-1,239.087.4-566.9-709.2-420.9

Income tax (AUD K)

00000

Net profit (AUD K)

-1,239.087.4-566.9-709.2-420.9

EPS basic (cents)

-5.130.36-2.35-2.94-1.74

EPS diluted (cents)

-5.130.36-2.35-2.94-1.74

Dividends per share (cents)

00000

Margin Analysis (%)

MetricFY2022FY2023FY2025FY2026

Net margin on total income (%)

—9.6-387.6-68.0

Expenses / average equity (%)

13.511.113.817.6

Expenses ex-impairment / average equity (%)

7.87.513.817.6

Total income growth YoY (%)

———238.3

Balance Sheet and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (AUD K)

7,710.67,738.5—6,550.66,762.4

Cash and equivalents (AUD K)

1,334.93,287.73,540.23,153.03,778.2

Investments at fair value (AUD K)

6,115.54,416.13,726.23,370.62,940.3

Other receivables (AUD K)

225.79.7—2.018.8

Total liabilities, all trade payables (AUD K)

395.1335.6—423.91,056.5

Short-term debt (AUD K)

00000

Long-term debt (AUD K)

00000

Net debt, negative = net cash (AUD K)

-1,334.9-3,287.7-3,540.2-3,153.0-3,778.2

Total equity (AUD K)

7,315.67,402.96,836.06,126.85,705.8

Goodwill and intangibles (AUD K)

00000

Working capital (AUD K)

7,315.67,402.96,836.06,126.85,705.8

Book value per share (cents)

30.330.628.325.423.6

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (AUD K)

-676.01,952.8252.5-387.2625.1

Payments for investments (AUD K)

-7,201.1-3,027.5—-2,406.7-1,985.2

Proceeds from sale of investments (AUD K)

6,721.44,866.0—2,418.42,345.5

Capex (AUD K)

00000

Free cash flow (AUD K)

-676.01,952.8252.5-387.2625.1

Dividends paid (AUD K)

00000

Buybacks (AUD K)

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2022FY2023FY2024FY2025FY2026

ROE on average equity (%)

-15.61.2-8.0-10.9-7.1

Company-reported return on average capital employed (%)

-171—-11-7

ROA on closing assets (%)

-16.11.1—-10.8-6.2

Liquidity ratio: total assets / liabilities (x)

19.523.1—15.56.4

Debt to equity (x)

00000

Cash / total assets (%)

17.342.5—48.155.9

Asset turnover: total income / closing assets (x)

—0.12—0.030.09

Revenue by Region

RegionFY2024FY2025FY2026

Australia (AUD K)

—183.0619.1

Offshore (AUD K)

000

Capital Markets Data (AUD) and Per-Share Data

MetricFY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026

Share price at 30 June (AUD)

0.710.210.310.220.220.220.180.18

Reported NTA before deferred tax (AUD)

0.330.300.350.300.31—0.250.24

Book value per share, computed (AUD)

——0.3540.3030.3060.2830.2540.236

Price discount to book value (%)

——12.427.428.122.329.123.7

Net profit (AUD K)

-9,821.5-750.21,260.8-1,239.087.4-566.9-709.2-420.9

Month-end Details

Month-endNTA (cents)Monthly gross portfolio return

Dec 2024

25.94—

Jan 2025

26.44+2.38%

Jun 2025

25.52+1.60%

Dec 2025

26.68+0.92%

Jan 2026

27.31+3.85%

Feb 2026

26.11-3.32%

Apr 2026

25.36+1.92%

Jul 2026

34.10

+1.40% (includes settlements)

Share Price History

PeriodStart price (AUD)End price (AUD)Change

1 year (about Oct 2025 to Oct 2026)

about 0.185

0.255

about +38%

3 years (30 Jun 2023 to latest)

0.220.255

about +16%

5 years (30 Jun 2021 to latest)

0.310.255

about -18%

Valuation Snapshot

MultipleValueComment

EV/Sales (total income)

About 3.9x

A$2.38m ÷ A$0.619m; low relevance for an LIC

P/B (30 June 2026 book)

About 1.08x

A$0.255 ÷ A$0.236

Price / latest NTA (31 Jul 2026)

About 0.75x (about a 25% discount)

A$0.255 ÷ A$0.341

Price / NTA including deferred tax assets

About 0.55x

A$0.255 ÷ (A$0.341 + about A$0.12)

Capital Markets

ItemDetail

Analyst consensus

None. BHD is not covered by a major broker (Market Index)

Dividend history

No dividends in FY2019–FY2026. Dividends and a DRP were declared under the former manager in FY2018

Dividend policy

No current policy; profit reserve of A$1.50m earmarked for future dividends; franking credits of A$510k

Buy-back authorisations

None current. The FY2023 report confirms no on-market buy-back; one existed under the former manager in 2018

Credit ratings (Moody's / S&P / Fitch)

Not rated

Debt maturity profile

No debt

Liquidity

Average daily volume about 24,000–72,000 shares across TipRanks snapshots in 2025; 345 holders at Aug 2023

Analyst Conclusions

Management guidance. No quantitative guidance is provided. Qualitatively, the board will maintain its wide, opportunistic mandate with a capital-preservation bias. It does not anticipate further recoveries from the JB Markets judgment, and it has said it will consider capital management after the settlements (NTA, 14 August 2026; Litigation Update, 20 July 2026).

Consensus expectations. None. The company has no analyst coverage.

Bull case

  1. Discount closure through capital management. NTA of about 34.1 cents plus about 12 cents per share of unrecognised tax assets, against a A$0.255 share price, offers 34% upside to NTA alone. A buy-back, return of capital or wind-up would crystallise much of that gap.

  2. Costs should fall structurally. With litigation largely concluded, legal fees (A$565,697 in FY2026) could drop toward pre-2024 levels of about A$46k (FY2023). That would roughly halve the cost base and turn the portfolio's positive investment income (A$534,741 in FY2026) into a reported profit.

  3. Portfolio catalysts. Maturing Cordish Dixon funds bought at discounts (18% of the portfolio), HealthCo REIT and Kyron Capital re-ratings, and higher interest income on about A$6.4m of pro forma cash could lift NTA independently of the litigation.

Bear case

  1. Fixed costs keep eroding value. Even without legal costs, directors' fees of A$308k (including additional "recovery" fees that may persist) equal about 3.7% of pro forma NTA a year. Equity has already fallen 33% since 1 July 2021.

  2. Contested register and governance risk. Insiders and related LICs control over half of the register, and Keybridge holds a further 15%. Disagreement over capital management could trigger further costly contests, as seen in the 2025 Takeovers Panel matters and the remuneration strikes.

  3. The discount may persist. BHD has traded 22–29% below book value at every year-end since FY2022, despite stable NTA. Without a binding capital return, illiquidity and nano-cap status may keep it there.

Key catalysts and monitorables for the next 12 months

  • Audited FY2026 Annual Report: confirm the settlement accounting, the fee arrangements and any going-concern commentary.

  • 2026 AGM: Remuneration Report vote (strike history), director re-elections, any capital-management resolutions.

  • Announcement of a buy-back, return of capital, special dividend or corporate transaction.

  • Monthly NTA trend: does NTA hold about 34 cents once settlement-related legal accruals are paid?

  • Whether Miller and Ravell's additional fees cease now that recoveries have occurred.

  • Progress of the McAuliffe and Elderfield criminal trial in the Queensland District Court.

  • Register changes: identity of the July 2026 substantial holder; the actions of Keybridge and GC1.

  • Cordish Dixon distributions and outcomes for HealthCo and Kyron.

Analyst verdict. Benjamin Hornigold Ltd is best understood not as an operating investment franchise but as a balance-sheet situation that has reached its endgame. The 2017–2018 related-party transactions with John Bridgeman Ltd destroyed most of the original capital: issued capital is A$23.5m against net assets of A$5.7m at June 2026. They also left the company with impaired claims, a governance stigma and a register shaped by activists. The 2019 board has done the essential work. It stabilised the portfolio, kept a large cash buffer, avoided external fees and, in mid-2026, converted years of litigation into A$2.6m of cash, lifting NTA to about 34 cents per share.

The economics remain fragile, however. FY2026 showed a portfolio that made money (A$534,741 of net investment income) inside a company that lost money (A$420,931), because costs ran at about 17.6% of equity. With the litigation essentially exhausted, the case for continuing as a standalone A$8m LIC is weak on cost grounds alone. The rational value-maximising paths are capital return, buy-back, merger with a related vehicle or orderly wind-up. Any of these would tend to close a discount of about 25% to NTA, and a merger could also extract value from about A$3.1m of tax-effected losses.

The main risks are inertia, meaning the board keeps the vehicle running with a fixed cost base that steadily erodes NTA, and conflict among the concentrated holders. These include the Chair's own GC1 vehicle, director Ravell and Keybridge.

On balance, BHD offers asymmetric, event-dependent value for patient holders of a highly illiquid security. The investment outcome depends almost entirely on board decisions over the next two to three reporting periods, not on markets. The audited FY2026 Annual Report and the 2026 AGM are the decisive near-term tests.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleAppointedQualificationsBackgroundOther listed directorships

Michael Glennon

Non-Executive Chairman; Company Secretary

12 Jun 2019

Bachelor of Commerce

CIO and Portfolio Manager at Glennon Capital Pty Ltd; small-cap portfolio manager since 1999; co-founder of several boutique funds-management firms

Glennon Small Companies Ltd (ASX: GC1) since 29 Apr 2015; formerly Excelsior Capital Ltd (ASX: ECL), resigned 4 Oct 2019

Gary Miller

Non-Executive Director; Chair of Audit & Risk and Remuneration Committees

12 Jun 2019

Diploma of Financial Advising

About 30 years in financial markets; director (2011–April 2020) and Responsible Officer of Miller Wealth Management Pty Ltd (AFSL holder 2011–2020); former partner in a Brisbane financial-planning firm; former investment committee member of an ASX-listed financial services group; commercial property and development finance experience

—

Sulieman Ravell

Non-Executive Director

12 Jun 2019

BEng (Hons), AFPC (UK), ADFP, Cert IV Mortgage Services

25+ years in financial services; Representative Director and Responsible Manager of NW Advice Pty Ltd and Wealth Focus Pty Ltd; former member of the Filtered Research Committee

Glennon Small Companies Ltd (ASX: GC1) since 9 Jun 2020

Directors' Remuneration

DirectorFY2026 feesFY2026 superannuationFY2026 totalFY2025 total

M Glennon

75,0009,00084,00083,625

G Miller

100,00012,000112,000111,500

S Ravell

100,00012,000112,000111,500

Total

275,000

33,000

308,000

306,625

Board & Management Changes

DateChangeContext

Jun 2019

Entire prior board, including CEO Stuart McAuliffe, resigns; Glennon, Miller and Ravell appointed

Governance crisis after related-party payments to JBL and the 2018 suspension

Since Jun 2019

No changes

Board stable for over seven years

Major Shareholders

HolderShares%Date / source

J P Morgan Nominees Australia Pty Ltd (nominee)

5,429,88022.48

Market Index

Glennon Capital Pty Ltd (via Glennon Small Companies Ltd, GC1); linked to Chair Michael Glennon

5,170,17421.40

InvestSMART substantial holders; FY2026 Remuneration Report

Keybridge Capital Ltd

3,727,06715.43

Market Index; InvestSMART

Sulieman Ravell interests (S4 Super, S4 Family Trust, Wealth Focus)

2,732,17411.31

FY2026 Remuneration Report

Dawney & Co Ltd

2,907,89212.04—

Hurlbook Pty Ltd (Skitt Family Super Fund)

1,385,0005.73

FY2023 top 20

GTM Family Super Pty Ltd (Gary Miller)

1,207,1305.00

FY2026 Remuneration Report

John Charles Plummer and associates

1,239,8075.13

FY2023 substantial holders

Barracuda Capital Pty Ltd

922,5653.82

FY2023 top 20

Co Super Pty Ltd (Rojek Super Fund)

489,6902.03

FY2023 top 20

Competitive Landscape

Key Competitors

Peer (ASX code)Relevance to BHDRelative positioning

Glennon Small Companies Ltd (GC1)

Same Chair and portfolio-management lineage; 21.4% BHD holder

Related party rather than an arm's-length competitor; small-cap growth mandate

Keybridge Capital Ltd (KBC)

15.4% BHD holder; also a legacy-asset, deep-value vehicle; entered administration in early 2025

Activist counterparty; contested control history

WAM Capital and other Wilson Asset Management LICs (WAM family)

Linked to the Keybridge requisition; dominant player in LIC discount-capture and market-driven strategies

Far larger scale and brand; sets the competitive benchmark for discount capture

Sandon Capital Investments (SNC)

Activist, event-driven micro/small-cap LIC

—

Thorney Opportunities (TOP)

Deep-value, event-driven micro-cap LIC

Similar style; listing status to be verified

Ryder Capital (RYD)

Concentrated, absolute-return small-cap LIC

—

NAOS Emerging Opportunities (NCC) and related NAOS LICs

Concentrated small and micro-cap; BHD held a NAOS Ex-50 convertible bond in 2023

Status after any sector consolidation to be verified

Flagship Investments (FSI)

Small, long-running ASX LIC

Comparable micro-scale vehicle

Acorn Capital Investment Fund (ACQ)

Listed and unlisted micro-cap fund

Comparable hybrid of listed and unlisted exposure

Bailador Technology Investments (BTI)

Listed vehicle for unlisted growth investments; held by BHD in 2023

Example of a discounted closed-end vehicle BHD targets

Peer Comparison FY2026

MetricBHD (FY2026)Peer 1Peer 2Peer 3

Net assets

A$5.71m

———

Total income growth

+238%———

Net margin on income

-68%———

Expense / average equity

17.6%———

R&D intensity

0% (not applicable)

0%0%0%

Management fee

Nil (self-managed)

———

Recent Developments

No layoffs, hiring, guidance revisions or regulatory actions against the company itself occurred in the period. The ASIC actions concern former officers and JBL-group entities.

Company Snapshot

2016

Founded

Sydney, Australia

Headquarters

SWOT Analysis

Strengths

  • No debt and large liquidity. Cash of A$3,778,188 equals 55.9% of total assets at 30 June 2026; total liabilities are only A$1,056,538 (FY2026 Appendix 4E).
  • Cash windfall after balance date. A$2.6m of settlements was received in July–August 2026, equal to about 46% of 30 June 2026 net assets (FY2026 Note 20).
  • Fee-free structure. There has been no external management or performance fee since 2019; the only remuneration is fixed directors' fees of A$308k (FY2026 Remuneration Report).
  • Tax assets. Unrecognised tax losses (tax-effected) total A$3,058,299, and the NTA excludes about 12 cents per share of deferred tax assets (FY2026 Note 7; NTA, August 2026).
  • Franking and profit reserve. Franking credits of A$510,016 and a profit reserve of A$1,496,543 are available for future dividends (FY2026 Notes 13 and equity).
  • Aligned board. Directors hold 37.7% of shares, and Ravell bought 356,147 shares on market in FY2026 (FY2026 Remuneration Report).
  • Portfolio resilience. The FY2022 gross return of -5.97% compared with -19.5% for the Small Ordinaries Accumulation Index (FY2022 Financial Report).

Weaknesses

  • Punitive cost base. Total expenses of A$1,040,065 equalled 17.6% of average equity in FY2026 (computed from the FY2026 Appendix 4E).
  • Chronic losses. The company lost money in four of the last five years, A$2.85m cumulatively over FY2022–FY2026 (Remuneration Report tables).
  • Shrinking equity. Equity fell from A$8.55m (1 July 2021) to A$5.71m (30 June 2026) (statements of changes in equity).
  • Benchmark underperformance. The board itself disclosed that the portfolio underperformed the S&P/ASX 200 Accumulation Index in FY2026, and in FY2023 it returned 9.83% against 14.7% for the index (Remuneration Reports; FY2023 letter).
  • Compliance lapses. The company was suspended for one day on 15 June 2026 for a late NTA filing (ASX notice), and issued a corrected 2025 AGM notice for typographical errors.
  • Governance concentration. The Chair is also Company Secretary and de facto portfolio manager, the Audit & Risk Committee is the full board, and two directors share another listed board (FY2023 Directors' Report).
  • Weak shareholder support for pay. A first strike was recorded on the 2024 Remuneration Report, followed by a potential spill at the 2025 AGM (TipRanks summary of the AGM notice).

Opportunities

  • Capital management. A buy-back, return of capital or special dividend at the current discount would be accretive. At A$0.255 the shares trade about 25% below the 34.10-cent July 2026 NTA.
  • Lower costs. Legal fees (A$565,697 in FY2026) should fall sharply now that the board expects no further recoveries from the current proceedings (Litigation Update, July 2026).
  • Private-equity distributions. The Cordish Dixon funds (18.06% of the portfolio) are maturing and distributing, and fund distributions rose 50% to A$616,819 in FY2026.
  • Discount-closure positions. HealthCo REIT (6.10%) and Kyron Capital (3.11%) are positioned for re-rating catalysts (NTA, August 2026).
  • Using tax losses. About A$12.2m of gross tax losses (A$3.06m ÷ 25%) could shelter future gains or add value in a merger with a profitable LIC. This is an analyst inference.
  • Corporate transaction. Related or activist holders (GC1 at 21.4%, Keybridge at 15.4%) could support a merger or restructuring.

Threats

  • Value leakage from fixed costs. Directors' fees of about A$308k a year equal about 3.7% of pro forma NTA of about A$8.3m, before any other costs (computed).
  • Register conflict. Keybridge and the WAM-associated parties have a record of contested-control litigation (Takeovers Panel TP25/003, /010, /017).
  • Market risk. A 5% fall in market prices would cut net assets by A$147,871 (FY2026 Note 14).
  • Tenant and credit risk in deep-value holdings. HealthCo's exposure to Healthscope uncertainty and Kyron's covenant history (NTA, August 2026).
  • Illiquidity and the discount. The shares are thinly traded and the price has historically sat 20–30% below NTA (Remuneration Report price vs NTA tables).
  • Uncertain settlement accounting. The settlements are described inconsistently (former directors vs loans), and the FY2026 statements are unaudited (FY2026 Appendix 4E, items 15–16).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
26 Mar 2025Takeovers Panel publishes reasons for declining BHD's applications concerning Keybridge and BHDCloses the Panel route; disputes continue in the NSW Supreme Court
Apr 2025Monthly NTA report for March 2025Routine disclosure
May–Jun 2025Monthly NTA reports; continued pursuit of JBL and JBFG debtsLitigation narrative maintained
20 Jun 2025Prosecutions of McAuliffe and Elderfield mentioned in Brisbane Magistrates Court; trial to be heard in the Queensland District CourtCriminal case still unresolved
Jul 2025June 2025 NTA of 25.52 cents; gross monthly portfolio return of 1.60%FY2025 year-end NTA baseline
26 Aug 2025Annual Report for June 2025 released (FY2025 loss A$709,247)Fourth loss in five years
29 Aug 2025Preliminary Final Report for FY2025Statutory filing
15–19 Sep 20252025 AGM Notice and Letter issued; corrected notice fixes typographical errors (date; Miller re-election; Remuneration Report wording)Governance quality signal
Sep–Oct 2025AGM notice warns of a potential spill resolution following the prior first strikeShareholder dissent risk
23 Oct 2025AGM held; AGM presentation and results lodgedBoard remained intact (per FY2026 report)
29 Oct 2025Court-ordered mediation with two former directors failsMatter proceeds to a final hearing
4 Nov 2025Litigation update: mediation failed; final hearing to be listed; recap of the ASIC actionsSets up the July 2026 hearing
14 Jan 2026December 2025 NTA of 26.68 cents; monthly return +0.92%Steady NTA
13 Feb 2026January 2026 NTA of 27.31 cents; monthly return +3.85%Six-month NTA high before the settlements
25 Feb–3 Mar 2026Director Ravell buys 42,038 shares on market at about A$0.185–0.188 (Appendix 3Y, 2 Mar 2026)Insider buying
26–27 Feb 2026Half-year report to 31 Dec 2025: net gain from investment portfolio A$646,978 (prior half: loss A$156,865); NTA 26 centsImproved portfolio performance
13 Mar 2026February 2026 NTA of 26.11 cents; monthly return -3.32%Market drawdown
13 May 2026April 2026 NTA of 25.36 cents; monthly return +1.92%Pre-settlement trough area
15 Jun 2026ASX suspends BHD under Listing Rule 17.5 for failing to lodge its May 2026 NTA report on timeCompliance lapse
16 Jun 2026Reinstated to quotation after lodging the May 2026 NTAResolved within one trading day
29 Jun 2026Litigation update: A$800,000 settlement deed with a former director, subject to one conditionFirst cash recovery in years
9 Jul 2026Insurer sign-off satisfies the settlement condition; "Becoming a substantial holder" notice lodged the same daySettlement unconditional; register change
13 Jul 2026June 2026 NTA reportYear-end NTA
20 Jul 2026Litigation update: A$1.8m settlement with a previous director; no further funds expected from current proceedings; board to explore capital management options. A$0.8m received in the solicitors' trust accountMajor value event: share price moved from about A$0.18 toward A$0.21–0.26
4 Aug 2026A$1.8m settlement funds received in the company's bank accountCash in hand
6 Aug 2026Default judgment of A$8,971,570 against JB Markets Pty LtdNo value attributed
14 Aug 2026July 2026 NTA of 34.10 cents (+1.40% portfolio return) incorporates the settlementsNTA up about 34% on April 2026
31 Aug 2026Unaudited FY2026 Appendix 4E: loss of A$420,931 (41% narrower); NTA A$0.24 at 30 June 2026Final results; audited Annual Report to follow

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Income Statement: Revenue & Gross Profit: Other revenue / cost recoveries fell from AUD 0.1 Mn in FY2022 to AUD 0 Mn in FY2026.
Benjamin Hornigold Limited — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2022FY2023FY2025FY2026
Other revenue / cost recoveries0.1000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.